Home > Rheumatology > ACR 2021 > Late-Breaking Abstracts > IL-17 inhibition showing efficacy in GCA in phase 2 trials

IL-17 inhibition showing efficacy in GCA in phase 2 trials

Presented By
Prof. Jens Thiel, Medical University Graz, Austria
Conference
ACR 2021
Trial
Phase 2, TitAIN
The IL-17 inhibitor secukinumab showed efficacy in giant cell arteritis (GCA) in a phase 2 trial. The drug will now be investigated in a phase 3 trial towards defining a future role in disease. “Experimental and pre-clinical data points to the fact that IL-17A has a role in the pathogenesis of GCA,” Prof. Jens Thiel (Medical University Graz, Austria) stated [1]. This was the rationale to perform the phase 2 TitAIN trial (EudraCT 2018-002610-12), the first randomised, parallel-group, double-blind, placebo-controlled, multicentre trial of secukinumab in patients with GCA. Included participants had new-onset or relapsing GCA and were naïve to biological therapy. They were randomised to secukinumab 300 mg (n=27) or placebo (n=25), initially administered weekly for 5 weeks and then every 4 weeks through week 48 (las...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on